Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer

Background The induction of reactive oxygen species (ROS) represents a viable strategy for enhancing the activity of radiotherapy. The authors hypothesized that napabucasin would increase ROS via its ability to inhibit NAD(P)H:quinone oxidoreductase 1 and potentiate the response to chemoradiotherapy in rectal cancer via distinct mechanisms. Method Proliferation studies, colony formation assays, and ROS levels were measured in HCT116 and HT29...